Cognitive Performance, Mood
Conditions
Brief summary
This study investigated the potentially cognitive enhancing effects of 500mg trans-resveratrol in healthy, young humans.
Interventions
DIETARY_SUPPLEMENTTrans-resveratrol
In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
OTHERPlacebo
In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
Sponsors
Northumbria University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* 18-35yrs, healthy.
Exclusion criteria
* Drug/alcohol abuse, taking prescription medication (apart from contraception) or herbal supplements, having food intolerances or allergies, having suffered a head-injury or neurological/neuro-developmental disorder, uncorrected sight problems, pregnant or seeking to become so, excessive caffeine use (e.g. more than 6 cups of coffee per day).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with altered cognitive function at 6hrs post-dose | 6hrs post-dose | This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 6hr post-dose scores. |
| Number of participants with altered cognitive function at 40mins post-dose | 40mins Post-dose | This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from the baseline to 40min post-dose scores. |
| Number of participants with altered cognitive function at 2.5hrs post-dose | 2.5hrs post-dose | This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 2.5hr post-dose scores. |
| Number of participants with altered cognitive function at 4hrs post-dose | 4hrs post-dose | This outcome measure is assessed by the number of participants whose scores on a range of cognitive tasks (word and picture recall and recognition, serial 3s and 7s subtractions, rapid visual information processing (RVIP), N-Back (3-Back version), Stroop and numeric working memory) differed from baseline to the 4hr post-dose scores. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with altered mood at 40mins post-dose. | 40mins post-dose | This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 40mins post-dose scores. |
| Number of participants with altered mood at 2.5hrs post-dose | 2.5hrs post-dose | This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 2.5hrs post-dose scores. |
| Number of participants with altered mood at 4hrs post-dose | 4hrs pos-dose | This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 4hrs post-dose scores. |
| Number of participants with altered mood at 6hrs post-dose | 6hrs post-dose | This outcome was assessed by the number of participants whose baseline mood scores (as assessed by the Bond-Lader mood scale which categorises 'alert', 'content' and 'calm') differed from the 6hrs post-dose scores. |
Countries
United Kingdom
Outcome results
None listed